Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by JAFFER A AJANI and MARIELA BLUM MURPHY.
JAFFER A AJANI
Connection Strength
11.933
MARIELA BLUM MURPHY
  1. A Phase I/II Study of Docetaxel, Oxaliplatin, and Fluorouracil (D-FOX) Chemotherapy in Patients With Untreated Locally Unresectable or Metastatic Adenocarcinoma of the Stomach and Gastroesophageal Junction. Am J Clin Oncol. 2018 04; 41(4):321-325.
    View in: PubMed
    Score: 0.648
  2. Pathological complete response in patients with esophageal cancer after the trimodality approach: The association with baseline variables and survival-The University of Texas MD Anderson Cancer Center experience. Cancer. 2017 Nov 01; 123(21):4106-4113.
    View in: PubMed
    Score: 0.623
  3. Current concepts and future potential in neoadjuvant chemotherapy for esophageal cancer. Expert Rev Gastroenterol Hepatol. 2016; 10(3):383-92.
    View in: PubMed
    Score: 0.551
  4. Predictors of Survival in Patients with Resectable Gastric Cancer Treated with Preoperative Chemoradiation Therapy and Gastrectomy. J Am Coll Surg. 2015 Jul; 221(1):83-90.
    View in: PubMed
    Score: 0.528
  5. Long-term survival in patients with metastatic gastric and gastroesophageal cancer treated with surgery. J Surg Oncol. 2015 Jun; 111(7):875-81.
    View in: PubMed
    Score: 0.528
  6. Chemoradiation for esophageal cancer. Thorac Surg Clin. 2013 Nov; 23(4):551-8.
    View in: PubMed
    Score: 0.477
  7. Management of localized gastric cancer. J Surg Oncol. 2013 Mar; 107(3):265-70.
    View in: PubMed
    Score: 0.451
  8. Chemoradiation: Gastro-oesophageal cancer--is CROSSing over so hard to do? Nat Rev Clin Oncol. 2012 Sep; 9(9):493-4.
    View in: PubMed
    Score: 0.437
  9. Therapy: localized gastric cancer--a CLASSIC shift in the paradigm? Nat Rev Gastroenterol Hepatol. 2012 Mar 06; 9(4):194-5.
    View in: PubMed
    Score: 0.425
  10. Many a mickle makes a muckle. Translating a gastric cancer phenotype into a bigger thing. Onkologie. 2011; 34(10):499-500.
    View in: PubMed
    Score: 0.412
  11. A comprehensive review of S-1 in the treatment of advanced gastric adenocarcinoma. Future Oncol. 2011 Jun; 7(6):715-26.
    View in: PubMed
    Score: 0.404
  12. Nivolumab plus chemotherapy or ipilimumab versus chemotherapy in patients with advanced esophageal squamous cell carcinoma (CheckMate 648): 29-month follow-up from a randomized, open-label, phase III trial. Cancer Med. 2024 May; 13(9):e7235.
    View in: PubMed
    Score: 0.247
  13. SMARCA4 Mutations in Gastroesophageal Adenocarcinoma: An Observational Study via a Next-Generation Sequencing Panel. Cancers (Basel). 2024 Mar 27; 16(7).
    View in: PubMed
    Score: 0.245
  14. Therapeutic Advances in the Treatment of Gastroesophageal Cancers. Biomolecules. 2023 05 06; 13(5).
    View in: PubMed
    Score: 0.231
  15. Surveillance for esophageal cancer: does it make sense? J Natl Compr Canc Netw. 2012 Dec 01; 10(12):1590-2.
    View in: PubMed
    Score: 0.224
  16. Localized Gastroesophageal Adenocarcinoma in the Elderly: Is Age a Factor Associated with Suboptimal Treatment? Oncology. 2023; 101(3):153-158.
    View in: PubMed
    Score: 0.223
  17. Frequency and Implications of Paratracheal Lymph Node Metastases in Resectable Esophageal or Gastroesophageal Junction Adenocarcinoma. Ann Surg. 2021 04 01; 273(4):751-757.
    View in: PubMed
    Score: 0.199
  18. Preoperatively Treated Diffuse-Type Gastric Adenocarcinoma: Glucose vs. Other Energy Sources Substantially Influence Prognosis and Therapy Response. Cancers (Basel). 2021 Jan 23; 13(3).
    View in: PubMed
    Score: 0.197
  19. Integrated genomic profiling and modelling for risk stratification in patients with advanced oesophagogastric adenocarcinoma. Gut. 2021 11; 70(11):2055-2065.
    View in: PubMed
    Score: 0.196
  20. Total Lesion Glycolysis Assessment Identifies a Patient Fraction With a High Cure Rate Among Esophageal Adenocarcinoma Patients Treated With Definitive Chemoradiation. Ann Surg. 2020 08; 272(2):311-318.
    View in: PubMed
    Score: 0.190
  21. Nivolumab in Combination with Irinotecan and 5-Fluorouracil (FOLFIRI) for Refractory Advanced Gastroesophageal Cancer. Oncology. 2020; 98(5):289-294.
    View in: PubMed
    Score: 0.185
  22. Phase I Trial of Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) with Cisplatin, Mitomycin, and Paclitaxel in Patients with Gastric Adenocarcinoma and Associated Carcinomatosis or Positive Cytology. Ann Surg Oncol. 2020 Aug; 27(8):2806-2811.
    View in: PubMed
    Score: 0.184
  23. Multiplex profiling of peritoneal metastases from gastric adenocarcinoma identified novel targets and molecular subtypes that predict treatment response. Gut. 2020 01; 69(1):18-31.
    View in: PubMed
    Score: 0.176
  24. Ramucirumab and Paclitaxel Administered Every 2 Weeks (mRAINBOW Regimen) in Advanced Gastroesophageal Adenocarcinoma. Oncology. 2019; 96(5):252-258.
    View in: PubMed
    Score: 0.173
  25. Barrett's Esophagus after Bimodality Therapy in Patients with Esophageal Adenocarcinoma. Oncology. 2018; 95(2):81-90.
    View in: PubMed
    Score: 0.164
  26. Early Metabolic Change after Induction Chemotherapy Predicts Histologic Response and Prognosis in Patients with Esophageal Cancer: Secondary Analysis of a Randomized Trial. Target Oncol. 2018 02; 13(1):99-106.
    View in: PubMed
    Score: 0.160
  27. 101 Long-Term Survivors Who Had Metastatic Gastroesophageal Cancer and Received Local Consolidative Therapy. Oncology. 2017; 93(4):243-248.
    View in: PubMed
    Score: 0.154
  28. Comprehensive geriatric assessment in patients with gastric and gastroesophageal adenocarcinoma undergoing gastrectomy. J Surg Oncol. 2015 Dec; 112(8):883-7.
    View in: PubMed
    Score: 0.137
  29. Early versus Delayed Therapy of Advanced Gastric Cancer Patients--Does It Make a Difference? Oncology. 2015; 89(4):215-20.
    View in: PubMed
    Score: 0.134
  30. Geographic distribution of regional metastatic nodes affects the outcome of trimodality-eligible patients with esophageal adenocarcinoma. Oncology. 2015; 88(6):332-6.
    View in: PubMed
    Score: 0.131
  31. Medical management of gastric cancer: a 2014 update. World J Gastroenterol. 2014 Oct 14; 20(38):13637-47.
    View in: PubMed
    Score: 0.127
  32. Importance of surveillance and success of salvage strategies after definitive chemoradiation in patients with esophageal cancer. J Clin Oncol. 2014 Oct 20; 32(30):3400-5.
    View in: PubMed
    Score: 0.127
  33. Post-chemoradiation surgical pathology stage can customize the surveillance strategy in patients with esophageal adenocarcinoma. J Natl Compr Canc Netw. 2014 Aug; 12(8):1139-44.
    View in: PubMed
    Score: 0.126
  34. Distribution and timing of distant metastasis after local therapy in a large cohort of patients with esophageal and esophagogastric junction cancer. Oncology. 2014; 86(5-6):336-9.
    View in: PubMed
    Score: 0.124
  35. Anti-angiogenic agent ramucirumab: meaningful or marginal? Expert Rev Anticancer Ther. 2014 Apr; 14(4):367-79.
    View in: PubMed
    Score: 0.122
  36. Locoregional failure rate after preoperative chemoradiation of esophageal adenocarcinoma and the outcomes of salvage strategies. J Clin Oncol. 2013 Dec 01; 31(34):4306-10.
    View in: PubMed
    Score: 0.119
  37. Incidence of brain metastases after trimodality therapy in patients with esophageal or gastroesophageal cancer: implications for screening and surveillance. Oncology. 2013; 85(4):204-7.
    View in: PubMed
    Score: 0.118
  38. Results of the baseline positron emission tomography can customize therapy of localized esophageal adenocarcinoma patients who achieve a clinical complete response after chemoradiation. Ann Oncol. 2013 Nov; 24(11):2854-9.
    View in: PubMed
    Score: 0.118
  39. Propensity-based matching between esophagogastric cancer patients who had surgery and who declined surgery after preoperative chemoradiation. Oncology. 2013; 85(2):95-9.
    View in: PubMed
    Score: 0.117
  40. Ramucirumab: a novel antiangiogenic agent. Future Oncol. 2013 Jun; 9(6):789-95.
    View in: PubMed
    Score: 0.116
  41. Adjuvant therapy in gastric cancer: what is the optimal approach? Curr Oncol Rep. 2013 Apr; 15(2):146-51.
    View in: PubMed
    Score: 0.115
  42. Modern oncological approaches to gastric adenocarcinoma. Gastroenterol Clin North Am. 2013 Jun; 42(2):359-69.
    View in: PubMed
    Score: 0.114
  43. Association between clinical complete response and pathological complete response after preoperative chemoradiation in patients with gastroesophageal cancer: analysis in a large cohort. Ann Oncol. 2013 May; 24(5):1262-6.
    View in: PubMed
    Score: 0.112
  44. Outcome of trimodality-eligible esophagogastric cancer patients who declined surgery after preoperative chemoradiation. Oncology. 2012; 83(5):300-4.
    View in: PubMed
    Score: 0.110
  45. A nomogram associated with high probability of malignant nodes in the surgical specimen after trimodality therapy of patients with oesophageal cancer. Eur J Cancer. 2012 Dec; 48(18):3396-404.
    View in: PubMed
    Score: 0.109
  46. Clinical parameters model for predicting pathologic complete response following preoperative chemoradiation in patients with esophageal cancer. Ann Oncol. 2012 Oct; 23(10):2638-2642.
    View in: PubMed
    Score: 0.109
  47. Localized gastric cancer treated with chemoradation without surgery: UTMD Anderson Cancer Center experience. Oncology. 2012; 82(6):347-51.
    View in: PubMed
    Score: 0.108
  48. Advanced gastroesophageal carcinoma: an update on the current therapeutic landscape. Onkologie. 2012; 35(4):204-9.
    View in: PubMed
    Score: 0.107
  49. Gastric cancer: apples will always be apples. J Clin Oncol. 2012 Mar 20; 30(9):1017-8; author reply 1019-20.
    View in: PubMed
    Score: 0.106
  50. Nomograms for prognostication of outcome in patients with esophageal and gastroesophageal carcinoma undergoing definitive chemoradiotherapy. Oncology. 2012; 82(2):108-13.
    View in: PubMed
    Score: 0.106
  51. Celebrate or calibrate? We say calibrate. J Clin Oncol. 2011 Jul 01; 29(19):2732; author reply 2732-3.
    View in: PubMed
    Score: 0.101
  52. Updated Analysis of a Phase 2 Trial of Cytoreduction, Gastrectomy, and Hyperthermic Intraperitoneal Perfusion with Chemotherapy for Patients with Peritoneal Carcinoma from Gastric Cancer. Ann Surg Oncol. 2024 May; 31(5):2824-2825.
    View in: PubMed
    Score: 0.061
  53. Independent Stage Classification for Gastroesophageal Junction Adenocarcinoma. Cancers (Basel). 2023 Oct 25; 15(21).
    View in: PubMed
    Score: 0.060
  54. Clinical Impact of Positive Surgical Margins in Gastric Adenocarcinoma in the Era of Preoperative Therapy. Ann Surg Oncol. 2023 Aug; 30(8):4936-4945.
    View in: PubMed
    Score: 0.058
  55. Concurrent lymphovascular and perineural invasion after preoperative therapy for gastric adenocarcinoma is associated with decreased survival. J Surg Oncol. 2021 Mar; 123(4):911-922.
    View in: PubMed
    Score: 0.049
  56. Single-cell dissection of intratumoral heterogeneity and lineage diversity in metastatic gastric adenocarcinoma. Nat Med. 2021 01; 27(1):141-151.
    View in: PubMed
    Score: 0.049
  57. Tumor Regression Grade in Gastric Cancer After Preoperative Therapy. J Gastrointest Surg. 2021 06; 25(6):1380-1387.
    View in: PubMed
    Score: 0.047
  58. Impact of tumor regression grade on recurrence after preoperative chemoradiation and gastrectomy for gastric cancer. J Surg Oncol. 2020 Sep; 122(3):422-432.
    View in: PubMed
    Score: 0.047
  59. Efficacy of Three-Drug Induction Chemotherapy Followed by Preoperative Chemoradiation in Patients with Localized Gastric Adenocarcinoma. Oncology. 2020; 98(8):542-548.
    View in: PubMed
    Score: 0.047
  60. Potentially curable gastric adenocarcinoma treated without surgery. Eur J Cancer. 2018 07; 98:23-29.
    View in: PubMed
    Score: 0.041
  61. Factors associated with local-regional failure after definitive chemoradiation for locally advanced esophageal cancer. Ann Surg Oncol. 2014 Jan; 21(1):306-14.
    View in: PubMed
    Score: 0.030
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.